SE431202B - ANALOGY PROCEDURE FOR PREPARATION OF N-CYANOALKYL-P-HALOGENPHENOXY-ISOBUTYRAMIDES WITH BLOOD FAT CONTENTS - Google Patents
ANALOGY PROCEDURE FOR PREPARATION OF N-CYANOALKYL-P-HALOGENPHENOXY-ISOBUTYRAMIDES WITH BLOOD FAT CONTENTSInfo
- Publication number
- SE431202B SE431202B SE7802694A SE7802694A SE431202B SE 431202 B SE431202 B SE 431202B SE 7802694 A SE7802694 A SE 7802694A SE 7802694 A SE7802694 A SE 7802694A SE 431202 B SE431202 B SE 431202B
- Authority
- SE
- Sweden
- Prior art keywords
- preparation
- halogenphenoxy
- isobutyramides
- cyanoalkyl
- blood fat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Description
7802694-5 CH3 I R __. O-C-CO-NH2 + CH I CH3 basiskt medel 2=CH~(CH2)p-CN CH3 I 0-C-CO-NH- CH -CN , ( 2)n CH3 Uppfinningen beskrives närmare med följande exempel. 7802694-5 CH3 I R __. O-C-CO-NH 2 + CH 1 CH 3 basic agent 2 = CH 2 (CH 2) p -CN CH 3 I O-C-CO-NH-CH-CN, (2) n CH 3 The invention is further described by the following examples.
Exempel 1 N-cyanoetyl-p-klorfenoxi-isobutyramid I en 5 liters reaktor, försedd med uppvärmningsanordning, kylanord- ning och omrörare, framställdes vid 60°C en lösning av 1,220 g (5,71 mol) p~klorfenoxi-isobutyramid i 1,8 liter dioxan. Därefter tillsattes 23 g pulverformigt natriumkarbonat och långsamt (under minuter), under det att temperaturen höllss mellan 60 och 65°C, 394 ml akrylnitril. Reaktionsblandningen omrördes 15 minuter vid samma temperatur och filtrerades därefter under behandling med 60 g kolsvart. 1,6 liter dioxan sattes till filtratet och efter omrör- ning tillsattes lângsamt 10 liter avjoniserat vatten, varefter om- rörning upprätthölls 2 timmar och därefter fick reaktionsblandnin- gen vila 12 timmar. Efter separation av fällningen, tvätt med vat- ten och torkning vid 40°C erhölls 1,380 g av en beige produkt, som efter omkristallisation (isopropanol + vatten) gav 1,001 g (73%-igt utbyte) av en vit kristallin produkt, som smälte vid 71°C.Example 1 N-cyanoethyl-p-chlorophenoxy-isobutyramide In a 5 liter reactor, equipped with a heating device, cooling device and stirrer, a solution of 1.220 g (5.71 mol) of p-chlorophenoxy-isobutyramide was prepared at 60 ° C. , 8 liters of dioxane. Then 23 g of powdered sodium carbonate and 394 ml of acrylonitrile were added slowly (for minutes), while maintaining the temperature between 60 and 65 ° C. The reaction mixture was stirred for 15 minutes at the same temperature and then filtered while treating with 60 g of carbon black. 1.6 liters of dioxane were added to the filtrate and after stirring slowly 10 liters of deionized water were added, after which stirring was maintained for 2 hours and then the reaction mixture was allowed to rest for 12 hours. After separation of the precipitate, washing with water and drying at 40 DEG C., 1.380 g of a beige product were obtained, which after recrystallization (isopropanol + water) gave 1.001 g (73% yield) of a white crystalline product which melted. at 71 ° C.
Produktens analys stämde väl överens med formeln C13H15O2N2Cl.The analysis of the product was in good agreement with the formula C13H15O2N2Cl.
Exempel 2 N-cyanoetyl-p-fluorfenoxi-isobutyramid Förfarandet enligt exempel 1 upprepades, men p-klorfenoxi-isobutyr- amid användes i stället för p-fluorfenoxi-isobutyramid. Utbytet var 64% av en vit kristallin produkt med en smältpunkt av 75°C.Example 2 N-Cyanoethyl-p-fluorophenoxy-isobutyramide The procedure of Example 1 was repeated, but p-chlorophenoxy-isobutyramide was used instead of p-fluorophenoxy-isobutyramide. The yield was 64% of a white crystalline product with a melting point of 75 ° C.
Analysen överensstämde väl med formeln C13H15O2N2F. _ Exempel 3 N-cyanobutyl-p-klorfenoxi-isobutyramid Förfarandet enligt exempel 1 upprepades, men akrylnitril ersattes 7802-694-5 med pentylnitril. En vit kristallin produkt erhölls med ett 77%-igt utbyte och en smältpunkt av 88°C. Analysen överensstämde väl med formeln C15H19N2O2Cl.The analysis was in good agreement with the formula C13H15O2N2F. Example 3 N-Cyanobutyl-p-chlorophenoxy-isobutyramide The procedure of Example 1 was repeated, but acrylonitrile was replaced with pentylnitrile 7802-694-5. A white crystalline product was obtained with a 77% yield and a melting point of 88 ° C. The analysis was in good agreement with the formula C15H19N2O2Cl.
Toxicitet Den akuta toxiciteten bestämdes per os på möss och råttor med vanli- ga metoder. LD50-värdena är resp. 1 g/kg för möss och över 2,4 g/kg för råttor för föreningen enligt exempel 1.Toxicity Acute toxicity was determined per os in mice and rats by standard methods. The LD50 values are resp. 1 g / kg for mice and over 2.4 g / kg for rats for the compound of Example 1.
För föreningarna enligt exemplen 2 och 3 är LDSO-värdena 1,2 g/kg för båda för möss och över 2,5 g/kg för båda för råttor.For the compounds of Examples 2 and 3, the LDSO values are 1.2 g / kg for both for mice and above 2.5 g / kg for both for rats.
Den subaktua toxiciteten för föreningen enligt exempel 1 undersöktes på råttor vid doserna 40, 80 och 160 mg/kg per os, och ingen skill- nad noterades mellan de behandlade djuren och kontrolldjuren.The subactual toxicity of the compound of Example 1 was tested in rats at doses of 40, 80 and 160 mg / kg per os, and no difference was noted between the treated animals and the control animals.
Farmakologi Triton-test Experimentell hyperlipoidemi och hyperkolesterolemi inducerades på råttor av hankön genom íntraperitoneal injektion av triton (dos 5 ml/ kg). Dessa råttor behandlades omedelbart per os antingen med produk- ten enligt exempel 1 eller med 2-(4-klorfenoxi)-2-metyl-propansyra- etylester eller med nikotinsyra (tre grupper om vardera 10 djur) med samma doser. De bästa hypokolesterolemi-aktiviteterna återfanns för föreningen enligt uppfinningen och den första referensföreningen, under det att de bästa hypotriglyceridemi-aktiviteterna återfanns för den andra referensföreningen och föreningen enligt uppfinningen. ëliniska försök patienter behandlades för jämförelsens skull successivt med 2-(4-klorfenoxi)-2-metyl-propansyra-etylester - referensförening - (30 dagar, 2 g/dag) och efter 15 dagar utan behandling med förenin- gen enligt exempel 1 - förening enligt uppfinningen - (30 dagar, 2 g/dag).Pharmacology Triton test Experimental hyperlipoidemia and hypercholesterolemia were induced in male rats by intraperitoneal injection of triton (dose 5 ml / kg). These rats were immediately treated orally either with the product of Example 1 or with 2- (4-chlorophenoxy) -2-methyl-propanoic acid ethyl ester or with nicotinic acid (three groups of 10 animals each) at the same doses. The best hypocholesterolemia activities were found for the compound of the invention and the first reference compound, while the best hypotriglycerideemia activities were found for the second reference compound and the compound of the invention. For clinical comparison, patients were successively treated with 2- (4-chlorophenoxy) -2-methyl-propanoic acid ethyl ester - reference compound - (30 days, 2 g / day) and after 15 days without treatment with the compound of Example 1 - compound of the invention - (30 days, 2 g / day).
Medelvärdena i g/1 för de ursprungliga värdena, slutvärdena cch_ minskning av triglycerider, total kolesterolmängd och total lipid- mängd âterges i följande tabell. 4 7802694-5 Referensförening Förening enl. uppf.The mean values in g / l for the initial values, final values and decrease in triglycerides, total cholesterol and total lipid are given in the following table. 4 7802694-5 Reference association Association acc. opg.
Triglxcerider ursprungligt värde 1,011 (ï 0,090) 1,59 (1 0,155) sintvärae 1,137 (i 0,005) 1,002 (1 0,101) minskning 0,474 (i 0,102) 0,507 (i 0,000) Total mängd kolesterol ursprungligt värde 7 3,31 (1 0,121) 3,17 (3 0,151) sintvärae 2,05 (É 0,170) 2,70 (3 0,169) minskning 0,40 (ï 0,107) 0,47 (i 0,050) Total lipidmängd ursprungligt värde 9,985 (É 0,342) 9,94 (i 0,454) sintvärae 0,775 (i 0,491) 0,367 (i 0,431) minskning p1,210 (3 0,244) 1,572 (i 0,190) Aktiviteten av föreningen enligt uppfinningen förefaller vara den- samma för total mängd kolesterol men mer gynnsamt vad beträffar tri- glycerider och total mängd lipid.Triglycerides original value 1,011 (ï 0,090) 1,59 (1 0,155) sintvärae 1,137 (in 0,005) 1,002 (1 0,101) decrease 0,474 (in 0,102) 0,507 (in 0,,000) Total amount of cholesterol original value 7 3,31 (1 0,121) 3.17 (3 0.151) sintvärae 2.05 (É 0.170) 2.70 (3 0.169) decrease 0.40 (ï 0.107) 0.47 (in 0.050) Total lipid amount initial value 9.985 (É 0.342) 9.94 ( in 0.454) sintvärae 0.775 (in 0.491) 0.367 (in 0.431) decrease p1,210 (3 0.244) 1.572 (in 0.190) The activity of the compound according to the invention appears to be the same for total amount of cholesterol but more favorable in terms of triglycerides and total amount of lipid.
Administreringsform-dos Föreningarna enligt föreliggande uppfinning kan förekomma i vilken lämplig form som helst för human terapi. En lämplig fimmxför oral _ administrering kan t.ex. vara en geletinkapsel som innehåller: förening enligt ett av exemplen 0,500 g kiselsyra D 0,018 g talk 0,042 g 0,560 g Vad beträffar dosen för patienterna kan denna ligga mellan 0,5 och 4 g per dag. ___...Dosage Form Dosage The compounds of the present invention may be in any form suitable for human therapy. A suitable oral administration may be e.g. be a gelatin capsule containing: compound according to one of the examples 0.500 g silicic acid D 0.018 g talc 0.042 g 0.560 g As for the dose for patients, this may be between 0.5 and 4 g per day. ___...
Claims (2)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB10069/77A GB1557420A (en) | 1977-03-10 | 1977-03-10 | Preparation of isobutyramide derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
SE7802694L SE7802694L (en) | 1978-09-11 |
SE431202B true SE431202B (en) | 1984-01-23 |
Family
ID=9960874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE7802694A SE431202B (en) | 1977-03-10 | 1978-03-09 | ANALOGY PROCEDURE FOR PREPARATION OF N-CYANOALKYL-P-HALOGENPHENOXY-ISOBUTYRAMIDES WITH BLOOD FAT CONTENTS |
Country Status (26)
Country | Link |
---|---|
JP (1) | JPS53112823A (en) |
AR (1) | AR214560A1 (en) |
AT (1) | AT352104B (en) |
AU (1) | AU517807B2 (en) |
BE (1) | BE864075A (en) |
CH (1) | CH628321A5 (en) |
DE (1) | DE2810505C3 (en) |
DK (1) | DK105078A (en) |
EG (1) | EG13580A (en) |
ES (1) | ES467566A1 (en) |
FI (1) | FI780472A (en) |
FR (1) | FR2383167A1 (en) |
GB (1) | GB1557420A (en) |
HK (1) | HK28880A (en) |
IE (1) | IE46671B1 (en) |
IN (1) | IN147801B (en) |
LU (1) | LU79195A1 (en) |
MX (1) | MX4826E (en) |
MY (1) | MY8100067A (en) |
NL (1) | NL7802024A (en) |
NO (1) | NO143969C (en) |
NZ (1) | NZ186388A (en) |
OA (1) | OA05902A (en) |
PT (1) | PT67667B (en) |
SE (1) | SE431202B (en) |
ZA (1) | ZA78618B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE496032T1 (en) | 1999-02-24 | 2011-02-15 | Hoffmann La Roche | 4-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS |
TWI280239B (en) | 2003-07-15 | 2007-05-01 | Hoffmann La Roche | Process for preparation of pyridine derivatives |
DK1928427T3 (en) | 2005-09-23 | 2010-03-08 | Hoffmann La Roche | Hitherto unknown dosage formulation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE734725C (en) * | 1940-04-17 | 1943-04-30 | Ig Farbenindustrie Ag | Process for the preparation of formylamino-ª ‰ -propionitriles |
GB1064252A (en) * | 1963-09-19 | 1967-04-05 | Ici Ltd | Amides and pharmaceutical compositions containing them |
GB1041982A (en) * | 1963-09-30 | 1966-09-07 | Boots Pure Drug Co Ltd | Herbicidal compounds and compositions |
-
1977
- 1977-03-10 GB GB10069/77A patent/GB1557420A/en not_active Expired
-
1978
- 1978-02-01 ZA ZA00780618A patent/ZA78618B/en unknown
- 1978-02-06 IN IN94/DEL/78A patent/IN147801B/en unknown
- 1978-02-07 NZ NZ186388A patent/NZ186388A/en unknown
- 1978-02-14 FI FI780472A patent/FI780472A/en not_active Application Discontinuation
- 1978-02-16 PT PT67667A patent/PT67667B/en unknown
- 1978-02-17 BE BE185268A patent/BE864075A/en not_active IP Right Cessation
- 1978-02-21 AU AU33459/78A patent/AU517807B2/en not_active Expired
- 1978-02-23 NL NL7802024A patent/NL7802024A/en unknown
- 1978-02-24 CH CH200778A patent/CH628321A5/en not_active IP Right Cessation
- 1978-02-28 JP JP2168278A patent/JPS53112823A/en active Granted
- 1978-03-02 AT AT148978A patent/AT352104B/en not_active IP Right Cessation
- 1978-03-04 ES ES467566A patent/ES467566A1/en not_active Expired
- 1978-03-06 OA OA56427A patent/OA05902A/en unknown
- 1978-03-07 EG EG156/78A patent/EG13580A/en active
- 1978-03-08 AR AR271358A patent/AR214560A1/en active
- 1978-03-08 LU LU79195A patent/LU79195A1/en unknown
- 1978-03-09 IE IE483/78A patent/IE46671B1/en unknown
- 1978-03-09 MX MX786923U patent/MX4826E/en unknown
- 1978-03-09 NO NO780834A patent/NO143969C/en unknown
- 1978-03-09 SE SE7802694A patent/SE431202B/en unknown
- 1978-03-09 DK DK105078A patent/DK105078A/en not_active Application Discontinuation
- 1978-03-10 FR FR7806912A patent/FR2383167A1/en active Granted
- 1978-03-10 DE DE2810505A patent/DE2810505C3/en not_active Expired
-
1980
- 1980-05-22 HK HK288/80A patent/HK28880A/en unknown
-
1981
- 1981-12-30 MY MY67/81A patent/MY8100067A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IN147801B (en) | 1980-06-28 |
OA05902A (en) | 1981-05-31 |
PT67667A (en) | 1978-03-01 |
NZ186388A (en) | 1979-04-26 |
HK28880A (en) | 1980-05-30 |
ATA148978A (en) | 1979-02-15 |
MX4826E (en) | 1982-10-21 |
FR2383167A1 (en) | 1978-10-06 |
AR214560A1 (en) | 1979-06-29 |
AU517807B2 (en) | 1981-08-27 |
NO143969B (en) | 1981-02-09 |
JPS5715831B2 (en) | 1982-04-01 |
FI780472A (en) | 1978-09-11 |
AT352104B (en) | 1979-09-10 |
NO143969C (en) | 1981-06-03 |
NO780834L (en) | 1978-09-12 |
ES467566A1 (en) | 1978-10-16 |
MY8100067A (en) | 1981-12-31 |
NL7802024A (en) | 1978-09-12 |
BE864075A (en) | 1978-06-16 |
FR2383167B1 (en) | 1980-04-25 |
SE7802694L (en) | 1978-09-11 |
EG13580A (en) | 1981-12-31 |
AU3345978A (en) | 1979-08-30 |
CH628321A5 (en) | 1982-02-26 |
JPS53112823A (en) | 1978-10-02 |
DK105078A (en) | 1978-09-11 |
ZA78618B (en) | 1978-12-27 |
DE2810505B2 (en) | 1979-08-30 |
IE780483L (en) | 1978-09-10 |
IE46671B1 (en) | 1983-08-24 |
DE2810505C3 (en) | 1980-05-08 |
GB1557420A (en) | 1979-12-12 |
LU79195A1 (en) | 1978-06-28 |
PT67667B (en) | 1979-07-20 |
DE2810505A1 (en) | 1978-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018311976B2 (en) | Inhibitors of Plasma Kallikrein and uses thereof | |
DK159264B (en) | ANALOGY PROCEDURE FOR PREPARING D- (THREO) -1-ARYL-2-ACYLAMIDO-3-FLUOR-1-PROPANOL COMPOUNDS | |
SU873872A3 (en) | Method of preparing aminopropanol derivatives or their salts | |
EP0186252A2 (en) | Use of thiophene compounds for the manufacture of a medicament against tumours | |
SE431202B (en) | ANALOGY PROCEDURE FOR PREPARATION OF N-CYANOALKYL-P-HALOGENPHENOXY-ISOBUTYRAMIDES WITH BLOOD FAT CONTENTS | |
JPS6294A (en) | Novel glycerophosphoric acid derivative and salt and production thereof | |
CN105601650B (en) | Structure, the preparation and use of diethylenetriamine base Chinese blister beetle acid imide dimer derivate | |
SU1376943A3 (en) | Method of producing derivatives of aminopyridine hydroxide or quaternary salts thereof | |
US4806568A (en) | Gossypol derivatives | |
WO2022089556A1 (en) | C-myc protein inhibitor, preparation method therefor, and use thereof | |
RU2768824C1 (en) | 2-(phenyl(phenylimino)methyl)isoindoline-1,3-dione and method for production thereof | |
SU820658A3 (en) | Method of preparing 1-phenylethanolamine derivatives or their salts | |
JPS63135378A (en) | Butyrolactone derivative, production and use thereof | |
JPH05213980A (en) | Preparation and refining of medicine having antineoplasm action, octadecyl-(-2-(n-methyl- piperidino)-ethyl phosphate, and preparation of the medicine | |
KR810001697B1 (en) | New preparation of isobutyramide derivatives | |
SU940645A3 (en) | Process for producing derivatives of 1,1'-biphenyl-2-ylalkylamine | |
CN114940694B (en) | Steroid compound, preparation method thereof and application thereof in treatment of tumors related to p53 mutation | |
US2855401A (en) | Certain n-(aminophenoxy pentyl) sulfonamide or saccharine compounds and higher homologues | |
CN116120297B (en) | 1, 3-Dicyclopropyl-5-substituted cyclic triphosurea compound and application thereof as iron death inducer | |
JPS63227570A (en) | Isoquinoline derivative | |
NO126374B (en) | ||
US4443458A (en) | Aminocrotonyl 3,5-dinitropyridine useful as adjuncts to radiation therapy | |
DK156436B (en) | ANALOGY PROCEDURE FOR PREPARING 6,6'METHYL-BIS (2,2,4-TRIMETHYL-1,2-DIHYDROQUINOLINE) DERIVATIVES AND CONDENSATION PRODUCTS THEREOF | |
SU664453A1 (en) | -[-(dimethylamino) alkalamino] alkylamides of oximinoacetic acid of thetr salts exhibiting anticurare effect | |
WO2024098273A1 (en) | Anti-influenza virus phosphate ester compound and use thereof |